Come up with a name for your new list and we'll add to it:
Forty Seven raised a round of funding on December 06, 2017. Investors include
California Institute of Regenerative Medicine.
Forty Seven is a clinical-stage immuno-oncology company that is developing therapies licensed from Stanford University targeting cancer immune evasion pathways. The lead program Hu5F9-G4 is a monoclon…